Phosphorylation of FADD is critical for sensitivity to anticancer drug-induced apoptosis.

FADD has been shown to be phosphorylated at Ser194 at the G2/M transition of the cell cycle. Here we have investigated the contribution of this phosphorylation to apoptosis induced by anticancer drugs in two human prostate cancer cell lines, LNCaP and DU145. Both were arrested at G2/M and FADD was found to be phosphorylated at Ser194 on treatment with paclitaxel. Inhibition of paclitaxel-induced c-jun NH2-terminal kinase (JNK) activation by treatment with a specific inhibitor, SP600125, or overexpression of a dominant-negative mutant form of upstream kinases, MEK kinase 1 (MEKK1) and mitogen-activated protein kinase kinase (MKK) 7, significantly reduced the increase in phosphorylated FADD. It is noteworthy that pretreatment with paclitaxel significantly up-regulated MEKK1 expression, resulting in enhancement of etoposide- or cisplatin-induced MEKK1/MKK7-dependent JNK activation and apoptosis in LNCaP and DU145 cells. Interestingly, MEKK1 up-regulation and the synergistic effects of paclitaxel on anticancer drug-induced apoptosis were abolished by overexpression of mutant FADD (Ser194-->Ala). The results clearly show that FADD phosphorylation at Ser194 affects functions both upstream and downstream of the MEKK1/MKK7/JNK1 pathway and is closely associated with chemosensitivity in prostate cancer cells. This is the first report indicating that phosphorylated FADD plays an essential role in the mechanisms of amplifications of chemotherapy-induced apoptosis.

[1]  P. de Souza,et al.  Enhancement of paclitaxel activity against hormone-refractory prostate cancer cells in vitro and in vivo by quinacrine. , 1997, British Journal of Cancer.

[2]  David W. Anderson,et al.  SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[3]  M. Ott,et al.  Paclitaxel shows cytotoxic activity in human hepatocellular carcinoma cell lines. , 1999, Cancer letters.

[4]  E. Solary,et al.  Fas Ligand-independent, FADD-mediated Activation of the Fas Death Pathway by Anticancer Drugs* , 1999, The Journal of Biological Chemistry.

[5]  T. Garrington,et al.  MEK Kinase 1 (MEKK1) Transduces c-Jun NH2-terminal Kinase Activation in Response to Changes in the Microtubule Cytoskeleton* , 1999, The Journal of Biological Chemistry.

[6]  A. Bird,et al.  Fas-associated death domain protein interacts with methyl-CpG binding domain protein 4: A potential link between genome surveillance and apoptosis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[7]  M. T. Abreu-Martin,et al.  Mitogen-Activated Protein Kinase Kinase Kinase 1 Activates Androgen Receptor-Dependent Transcription and Apoptosis in Prostate Cancer , 1999, Molecular and Cellular Biology.

[8]  Mitsutoshi Nakamura,et al.  Contributions of mitogen‐activated protein kinase and nuclear factor kappa B to N‐(4‐hydroxyphenyl)retinamide–induced apoptosis in prostate cancer cells , 2002, Molecular carcinogenesis.

[9]  T. Kuroki,et al.  Protein kinase Cδ amplifies ceramide formation via mitochondrial signaling in prostate cancer cells , 2002 .

[10]  E. Hall,et al.  Taxol sensitizes human astrocytoma cells to radiation. , 1992, Cancer research.

[11]  S. Nagata,et al.  The Fas death factor , 1995, Science.

[12]  P. Krammer,et al.  CD95's deadly mission in the immune system , 2000, Nature.

[13]  P. Schiff,et al.  Taxol and radiation. , 1993, Journal of the National Cancer Institute. Monographs.

[14]  R. Gaynor,et al.  Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. , 2001, The Journal of clinical investigation.

[15]  S. Fuqua,et al.  Androgen Receptor Acetylation Governs trans Activation and MEKK1-Induced Apoptosis without Affecting In Vitro Sumoylation and trans-Repression Function , 2002, Molecular and Cellular Biology.

[16]  H. Ichijo,et al.  From receptors to stress-activated MAP kinases , 1999, Oncogene.

[17]  M. Jordan,et al.  Microtubules and actin filaments: dynamic targets for cancer chemotherapy. , 1998, Current opinion in cell biology.

[18]  A. Winoto,et al.  A function of Fas-associated death domain protein in cell cycle progression localized to a single amino acid at its C-terminal region. , 2003, Immunity.

[19]  T. Kuroki,et al.  Protein kinase Cdelta amplifies ceramide formation via mitochondrial signaling in prostate cancer cells. , 2002, The Journal of clinical investigation.

[20]  Arul M. Chinnaiyan,et al.  FADD, a novel death domain-containing protein, interacts with the death domain of fas and initiates apoptosis , 1995, Cell.

[21]  C. Widmann,et al.  Potentiation of apoptosis by low dose stress stimuli in cells expressing activated MEK kinase 1 , 1997, Oncogene.

[22]  Mitsutoshi Nakamura,et al.  c‐Jun NH2‐terminal kinase‐dependent fas activation contributes to etoposide‐induced apoptosis in p53‐mutated prostate cancer cells , 2003, The Prostate.

[23]  T. Fojo,et al.  Microtubule-interfering Agents Activate c-Jun N-terminal Kinase/Stress-activated Protein Kinase through Both Ras and Apoptosis Signal-regulating Kinase Pathways* , 1998, The Journal of Biological Chemistry.

[24]  David Wallach,et al.  Involvement of MACH, a Novel MORT1/FADD-Interacting Protease, in Fas/APO-1- and TNF Receptor–Induced Cell Death , 1996, Cell.

[25]  T. H. Wang,et al.  Paclitaxel‐induced cell death , 2000, Cancer.

[26]  C. Widmann,et al.  MEK Kinase 1, a Substrate for DEVD-Directed Caspases, Is Involved in Genotoxin-Induced Apoptosis , 1998, Molecular and Cellular Biology.

[27]  M. Peter,et al.  Phosphorylation of FADD/ MORT1 at Serine 194 and Association with a 70-kDa Cell Cycle-Regulated Protein Kinase1 , 2000, The Journal of Immunology.

[28]  Mitsutoshi Nakamura,et al.  Phosphorylation of Fas‐associated Death Domain Contributes to Enhancement of Etoposide‐induced Apoptosis in Prostate Cancer Cells , 2002, Japanese journal of cancer research : Gann.

[29]  C. Widmann,et al.  Differential Involvement of MEK Kinase 1 (MEKK1) in the Induction of Apoptosis in Response to Microtubule-targeted Drugsversus DNA Damaging Agents* , 1999, The Journal of Biological Chemistry.

[30]  Mitsutoshi Nakamura,et al.  Requirement of c‐jun for testosterone‐induced sensitization to N‐(4‐hydroxyphenyl)retinamide–induced apoptosis , 2003, Molecular carcinogenesis.